Indeed, MRX-2843 synergized with the BCL-2 inhibitor venetoclax in two ETP-ALL cell lines and provided increased anti-leukemia activity against ETP-ALL cells compared with either of the drugs alone. This evidence concerns the gene BCL2 and acute lymphoblastic leukemia.